Further, our evaluation of anti-CCP2, RF-IgM, and RF-IgA antibodies revealed that neither RF-IgM nor RF-IgA were associated with any of the cardiovascular structural outcomes, nor incident HF. The gene discussed is AGBL2; the disease is hydrops fetalis.